Abstract : Glioblastoma GBM is dif cult to completely cure by surgical treatment alone, and it is generally treated with a combination of surgery, radiotherapy, and chemotherapy. However, GBM is resistant to radiotherapy and chemotherapy, and complete cure cannot be achieved. Cancer stem cells CSC and survivin, which inhibit apoptosis, are considered as factors underlying tumor recurrence and the radiation-and drug-resistance of these tumors. We analyzed CSC and survivin expression in surgically excised specimens of malignant brain tumors to establish the relationships between the grades and CSC and survivin expression and between MIB-1 Ki-67 expression and resistance. No relationship was noted between the grades and CSC or survivin expression, or between MIB-1 and CSC expression or between Grade 3 and 4 MIB-1 and survivin expression, although a correlation was noted between MIB-1 and survivin expression in Grade tumors. These ndings suggested that CSC are consistently contained in tumor tissue at a specific rate regardless of the histological grade, and the apoptosis of cells with low-level proliferative and cell cycling activities does not occur because these cells do not respond to chemotherapy or radiation, being resistant to treatment.
Introduction
Among primary brain tumors, highly malignant, high-grade glioblastoma 59 and medulloblastoma 62
show a high incidence in males and frequently develop in the 40 50s age group. Glioblastoma GBM and medulloblastoma of grade , based on the WHO classification, grow rapidly and are fatal if untreated. Histologically, these brain malignancies show abundant cell division and necrosis, rapidly infiltrate the surrounding tissue, and disseminate to the meninx 1 . GBM and medulloblastoma are therefore highly malignant tumors associated with a poor prognosis and survival time shorter than 1 year. In addition, the therapeutic outcomes for patients with these tumors have not markedly improved over several decades. Glioblastoma consists of mature glioma, and reportedly, most are dedifferentiated atypical astrocytoma 2 REF. However, undifferentiated pluripotent cells with a self-replicating ability were recently reported in glioblastoma tissue REF 3 . Such cells, termed cancer stem cells CSC , were also identified in acute myelogenous leukemia 4 , breast cancer 5 , and other brain tumors [6] [7] [8] [9] , and CSC-targeting treatment methods are now being investigated. CSC are in the G0 phase of the cell cycle, present in tissue as a stem cell-specific side population SP cells in various cancer tissues and cancer cell lines including GBM, and have tumor-forming and treatment-resistant properties 7 10 . Recent investigations have thus focused on developing new anticancer drugs effective for CSC, a radiosensitizer application method aiming at increasing the effect of radiotherapy on CSC, and a CSC-targeting treatment using immunocytes 11 12 . Tumor progression in glioblastoma was also effectively inhibited by an anti-angiogenic treatment that blocks the vascular niche or portal for CSC and the surrounding tumor cells. Those studies also correlated both CSC expression and survival time with the clinical outcomes of patients with oligodendrocyte tumors, revealing CSC to be a useful prognostic factor 13 14 .
Survivin belongs to the inhibitors of the apoptosis IAP family, which all inhibit apoptosis by inhibiting caspase 15 . It is strongly expressed in embryonic cells, but it is expressed only in limited organs in adults, including the testis and thymus. Survivin is undetectable in adult tissue, but its overexpression was recently reported in human malignant tumors of the large intestine, breast, stomach, esophagus, liver, and ovary 16 . Patients overexpressing the survivin gene in their cancer cells have a poor prognosis, and anti-survivin antibody production occurs in the blood of cancer patients REF 17 18 . Furthermore, antisense inhibition of survivin gene expression in cancer cells induced apoptosis, and together, these findings prompted investigation of survivin as an immunotherapy target 19 . However, there is no reported association with either the growth of malignant brain tumors or the WHO grade with CSC and survivin expression pattern. In this study, we analyzed the association between WHO grade and CSC survivin expression to investigate the important relationship between WHO grade and treatment resistance.
Material and Methods

Subjects
In this study we investigated specimens surgically excised from 70 patients with malignant brain tumor from 1987 to 2000. The group comprised 32 patients with grade 2 astrocytoma, 4 patients with grade 3 astrocytoma, and 34 patients with grade 4 glioblastoma Table 1 .
Statistical analysis
Data were tested for significance using ANOVA and Bonferroni. Results were considered significant with a P value 0.05.
Fluorescent immunohistochemistry
Eighty-two sections in total from the specimens were deparaffinized, and then incubated in 0.3 H 2 O 2 for 5 min to remove endogenous peroxidase. The sections were then incubated in non-specific blocking reagent X0909, Dako, Glostrup, DK for 5 min to block nonspecific staining. Sections were first incubated with anti-PROM1 primary antibody 1:100, Abnova, Taipei, Taiwan for 1 hour at room temperature, and a secondary, TRIC-conjugated anti-rabbit IgG A21428, Life Technologies, USA in a humid chamber at 37 for 30 min. Sequentially, sections were incubated with anti-survivin 1:100, M2624, Dako and anti-Ki-67 MIB-1 1:100, M0722, Dako primary antibodies at 37 for 1 hour, and then a secondary antibody FITC-conjugated anti-mouse lgG A11001, Life Technologies, USA for 30 min. Sections were systematically counterstained with bisbenzimide H33342 Hoechst 33342 , and images were captured on a confocal microscope Meta Xpress Image Analysis . Table 1 lists the clinicopathological characteristics of malignant brain tumors in the 70 patients. To confirm the relationship between malignancy grade and proliferative ability, immunohistochemistry IHC analysis was performed using fluorescence labeled antibody detection. Typical morphological characteristics of the malignant brain tumors were examined by HE staining Fig. 1A , B, C .
Results
Clinicopathological characteristics of the patients
Results of immunostaining
MIB-1 protein is used as an index of prognosis in patients with malignant tumors because it marks cells undergoing nuclear division. The MIB-1-immunopositive rate was 3.72 in Grade astrocytoma, 4.57 in Grade anaplastic astrocytoma, and 8.8 in Grade glioblastoma, thus the proliferative ability of the cells increased with the histological grade Fig. 2A .
To detect undifferentiated CSC, we employed IHC using the anti-PROM antibody, Fig. 2B .
We then localized survivin to the tumor cell cytoplasm Fig. 1J , K, L . The survivinimmunopositive rate was 2.00 in Grade astrocytoma, 0.59 in Grade anaplastic astrocytoma, and 1.99 in Grade glioblastoma, again showing no significant difference in surviving expression among the tumor grades Fig. 2C .
Comparison of proliferative ability with PROM and survivin in each grade
PROM and survivin expressions relative to MIB-1 proliferative ability index were analyzed Survivin expression of the MIB-1 was significantly different among the tumor grades P 0.001 . Table 2 .
Discussion
Malignant brain tumors show strong resistance to postoperative chemotherapy and radiotherapy, and a correlation between CSC numbers in the tumor and the resistance mechanism has been suggested as a cause. CSC-induced resistance is considered to derive from the cells self-replicating and proliferative abilities and drug-eliminating ATP binding cassette ABC transporters. Survivin belongs to the inhibitor of apoptosis IAP family, and mediates cellular resistance by inhibiting cell death.
The present study found no significant difference in MIB-1expression between Grade and malignant brain tumors, but a significantly higher immunopositivity for this protein was noted in Grade tumors. However, no significant difference was noted in PROM expression among Grades , , and . The relationship between MIB-1 and PROM was analyzed in each grade, but no significance was detected, showing that CSC accounted for a constant ratio of cells regardless of the grade of malignant brain tumor. No significant correlation was noted between Grade MIB-1 and Grade PROM expression, between Grade MIB-1 and Grade PROM expression, or between Grade MIB-1 and Grade PROM expression. Tumor cells with a high proliferation rate showing active cell cycling and CSC constantly arrested in the G0 phase may be not related to the grading, which is based solely on cells in the growth phase, and thus CSC and resistance due to survivin are not taken into consideration. This study suggested that treatment-resistant CSC in the G0 phase are constantly present at a specific rate in preoperative malignant brain tumors before radiotherapy and chemotherapy. CSC are maintained in the G0 phase resting phase , with the number, division, and resting phase of CSC controlled through interactions with the environment tissue microenvironment and cellular niche around CSC. The microenvironment called a niche for CSC to carry out the work as a stem cell is required. In addition, CSC have an inherent self-replicating ability, and we previously reported that CSC in the G0 phase differentiated and proliferated when cultured malignant brain tumor cells were irradiated at a high dose 20 21 , suggesting that, when radiation and chemotherapy are applied as postoperative treatment, it is important to set the treatment target at CSC and reduce the treatment resistance of CSC in the malignant brain tumor by destroying the CSC growthpromoting niche micro environment, which in turn induces the differentiation of CSC in the G0 phase, and inhibits molecules necessary for self-replication. Survivin is an IAP family protein, all of which contain the anti-apoptosis action-determining baculovirus IAP repeat BIR domain 22 . Two splice variants survivin2B and -Ex3 are transcribed from the survivin gene, and both have been reported to have an anti-apoptosis function. In addition, survivin expression level is related to the MIB-1 index and has been proposed as an index of tumor cell growth activity 23 . Regarding apoptosis signals, p53 activated by DNA injury promotes the transcription of Bax and PUMA p53 up-regulated modulator of apoptosis , which control cytochrome c release by regulating mitochondrial membrane permeability. Cytochrome c binds to Apaf-1 and forms an active complex with caspase 9, and this complex activates caspase 3 and 7, executing apoptosis. Survivin inhibits caspase 9 activity by binding to cofactor XIAP and thus acting as an anti-apoptosis factor. It was recently reported that sensitivity to existing drugs was enhanced by the functional inhibition of survivin using siRNA and ribozyme 24 25 . In this study, there was no significant difference in survivin expression among Grades , , and tissues. However, analysis within each grade uncovered a significant correlation between MIB-1-and survivin expression in Grade tumors. These findings suggested that malignant brain tumors show a specific level of apoptosis resistance regardless of the histological grade, and the proliferative ability and resistance of tumor cells are associated only in low-malignant Grade brain tumors. Apoptosis resistance in tumor cells with a low proliferative ability could reflect the numerous cells noted in the G0 phase. Since these cells are not actively progressing through the cell cycle, they do not respond to chemotherapy or show radiation sensitivity, and so do not undergo apoptosis.
Not all patients respond similarly to treatments of malignant brain tumors, and individualized treatment for patients is often necessary. The induction of apoptosis in treatment-resistant CSC and survivin-positive cells may therefore be useful for the treatment of malignant tumors. Since CSC are in the G0 phase, they must be induced to differentiate or undergo apoptosis. The therapeutic outcomes may be further improved by investigating tumor resistance coupled with a combination of differentiation induction in resistant cells and increasing sensitivity to radiotherapy and chemotherapy. Methods of killing CSC have been investigated, such as knocking out the self-replicating ability through inhibiting molecules necessary for self-replication and development of an antibody preparation against cell surface antigens specifically expressed by CSC, such as anti-CD44 antibody against HER2 for breast cancer 26 . The addition of therapies targeting treatment-resistant cells to the standard protocol may improve survival rates in patients with malignant brain tumors.
